Long-term hemoglobin A1c changes with apremilast in patients with psoriasis and psoriatic arthritis: Pooled analysis of phase 3 ESTEEM and PALACE trials and phase 3b LIBERATE trial

Background: Psoriasis and psoriatic arthritis (PsA) are associated with a high prevalence of metabolic syndrome and increased risk of diabetes. Apremilast, an oral phosphodiesterase 4 inhibitor, was efficacious in the treatment of patients (pts) with moderate to severe psoriasis in the phase 3 ESTEEM 1 and 2 (EST) and phase 3b LIBERATE trials and in the treatment of pts with active PsA in the phase 3 PALACE 1 –3 trials (PAL). To explore the potential effect of apremilast on A1c concentrations, we assessed A1c in pts receiving placebo (PBO) or apremilast in a pooled analysis of EST, LIBERATE, and PAL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research